Drug intelligence / Profile preview

ATG002

Development stage: Discontinued
Lead developer: CoMentis
Modality: Small Molecules
Administration: Topical

Overview

ATG002 is a small molecule drug that acts as an agonist of muscle-type nicotinic acetylcholine receptors (nAChRs). It was initially developed by CoMentis for the treatment of chronic wounds such as diabetic foot ulcers. The mechanism of action involves stimulation of angiogenesis through activation of muscle-type nAChRs, which may promote wound healing. The drug reached Phase 1/2 clinical trials but its development has been discontinued[1][4].

Other names: low-dose nicotine gelnicotine gel

Targets

Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on ATG002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATG002.

Explore the full profile